Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.51)
# 2,224
Out of 5,149 analysts
80
Total ratings
54.22%
Success rate
-0.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $17.72 | +108.80% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $33.01 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $23.94 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.53 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $239.22 | +6.18% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $2.38 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $34.31 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $7.17 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.50 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.67 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $6.15 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.36 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.07 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.43 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.50 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.00 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.53 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $5.31 | -43.50% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.37 | +264.96% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.57 | +1,378.60% | 1 | Aug 12, 2022 |
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $17.72
Upside: +108.80%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $33.01
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.94
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.53
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $239.22
Upside: +6.18%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.38
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.31
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $7.17
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.50
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.67
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $6.15
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.36
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.07
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.50
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.00
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.53
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $5.31
Upside: -43.50%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.37
Upside: +264.96%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.57
Upside: +1,378.60%